Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392558 | 0.89 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL392557 | 0.89 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL9105852 | 0.84 | MTOR (0.80) | MTOR | |
| SCHEMBL9100645 | 0.81 | MTOR (0.81) | MTOR | |
| SCHEMBL2906178 | 0.78 | MTOR (1.00) | MTOR | |
| SCHEMBL4175302 | 0.78 | MTOR (1.00) | MTOR | |
| SCHEMBL2907865 | 0.78 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL2901182 | 0.76 | MTOR (1.00) | MTOR | |
| SCHEMBL393861 | 0.76 | MTOR (0.79) | MTORAKT1 | |
| SCHEMBL1217634 | 0.75 | MTOR (1.00) | MTORAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435985-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MENEAR KEITH (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.